These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 18165268)

  • 21. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
    Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX
    Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma.
    Inandiklioğlu N; Yilmaz S; Demirhan O; Erdoğan S; Tanyeli A
    Asian Pac J Cancer Prev; 2012; 13(11):5391-7. PubMed ID: 23317189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.
    Ribatti D; Raffaghello L; Pastorino F; Nico B; Brignole C; Vacca A; Ponzoni M
    Int J Cancer; 2002 Dec; 102(4):351-4. PubMed ID: 12402304
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MYCN is retained in single copy at chromosome 2 band p23-24 during amplification in human neuroblastoma cells.
    Corvi R; Amler LC; Savelyeva L; Gehring M; Schwab M
    Proc Natl Acad Sci U S A; 1994 Jun; 91(12):5523-7. PubMed ID: 8202521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The DDX1 gene maps within 400 kbp 5' to MYCN and is frequently coamplified in human neuroblastoma.
    Amler LC; Schürmann J; Schwab M
    Genes Chromosomes Cancer; 1996 Feb; 15(2):134-7. PubMed ID: 8834178
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
    Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
    Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
    Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
    Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metachronous neuroblastoma in an infant with germline translocation resulting in partial trisomy 2p: a role for ALK?
    Morgenstern DA; Soh SY; Stavropoulos DJ; Bowdin S; Baruchel S; Malkin D; Meyn MS; Irwin MS
    J Pediatr Hematol Oncol; 2014 Apr; 36(3):e193-6. PubMed ID: 24276038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Methods of detection and prognostic significance of genetic material increase of the short arm of chromosome 2 and a deletion of the short arm of chromosome 1 in patients with neuroblastoma].
    Druĭ AE; Tsaur GA; Shorikov EV; Popov AM; Plekhanova OM; Typonogov SN; Savel'ev LI; Tsvirenko SV; Fechina LG
    Vopr Onkol; 2013; 59(5):591-8. PubMed ID: 24260886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The genetic and clinical significance of MYCN gain as detected by FISH in neuroblastoma.
    Souzaki R; Tajiri T; Teshiba R; Higashi M; Kinoshita Y; Tanaka S; Taguchi T
    Pediatr Surg Int; 2011 Mar; 27(3):231-6. PubMed ID: 21046119
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
    Alaminos M; Gerald WL; Cheung NK
    Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
    Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
    Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma.
    Alaminos M; Mora J; Cheung NK; Smith A; Qin J; Chen L; Gerald WL
    Cancer Res; 2003 Aug; 63(15):4538-46. PubMed ID: 12907629
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
    Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH
    Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633
    [TBL] [Abstract][Full Text] [Related]  

  • 35. cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma.
    Chen QR; Bilke S; Wei JS; Whiteford CC; Cenacchi N; Krasnoselsky AL; Greer BT; Son CG; Westermann F; Berthold F; Schwab M; Catchpoole D; Khan J
    BMC Genomics; 2004 Sep; 5():70. PubMed ID: 15380028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression profiles and clinical relationships of ID2, CDKN1B, and CDKN2A in primary neuroblastoma.
    Gebauer S; Yu AL; Omura-Minamisawa M; Batova A; Diccianni MB
    Genes Chromosomes Cancer; 2004 Dec; 41(4):297-308. PubMed ID: 15390183
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Investigation of MYCN status in neuroblastoma by fluorescence in situ hybridization.
    Wan TS; Ma ES; Chan GC; Chan LC
    Int J Mol Med; 2004 Dec; 14(6):981-7. PubMed ID: 15547663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma.
    Fulda S; Poremba C; Berwanger B; Häcker S; Eilers M; Christiansen H; Hero B; Debatin KM
    Cancer Res; 2006 Oct; 66(20):10016-23. PubMed ID: 17047064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis.
    Chen Y; Stallings RL
    Cancer Res; 2007 Feb; 67(3):976-83. PubMed ID: 17283129
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.
    Wang LL; Teshiba R; Ikegaki N; Tang XX; Naranjo A; London WB; Hogarty MD; Gastier-Foster JM; Look AT; Park JR; Maris JM; Cohn SL; Seeger RC; Asgharzadeh S; Shimada H
    Br J Cancer; 2015 Jun; 113(1):57-63. PubMed ID: 26035700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.